Strong Financial Performance: Stryker reported a double-digit organic sales growth of 10.2% for Q2 2025, an increase from 9% in Q2 2024. Adjusted EPS rose 11.4% to $3.13, driven by robust sales across the product portfolio, notably in MedSurg and Neurotechnology. The company anticipates full-year organic sales growth of 9.5% to 10% and an adjusted EPS range of $13.40 to $13.60, reflecting strong operational momentum and pricing improvements.

Segment Growth and Market Opportunities: Key segments, particularly Endoscopy and Orthopedics, showcased significant growth. Endoscopy achieved U.S. organic sales growth of 18.6%, attributed to high demand across various product offerings, while Orthopedics reported a 9% increase, supported by strong performance in robotic-assisted surgeries. There remains ample opportunity to expand in international markets, particularly with products pending approval in Europe and successful integration of acquisitions like Inari Medical.

Challenges in Supply Chain: While most of Stryker's supply chain is stable, challenges persist within the Medical segment, expected to impact sales growth throughout 2025. Despite these obstacles, the overall procedural volumes are anticipated to remain healthy, with double-digit growth in the latter half of the year driven by effective product demand and capital investments.